ONCE News and Press, Spark Therapeutics Inc.

Genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So, what is genetics investing? When it comes to genetics investing, companies in this niche...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking John Paulson's Paulson & Company Portfolio serie...

Sangamo Image Sangamo Therapeutics ( SGMO ) suffered through a second year of price declines prompted by ineffective clinical responses to their lead clinical gene editing or GE therapies. The company responded by placing all three GE clinical programs on hold as they work to increase dosing...

It does mean that a company with research centered around each of these divisions, like a cluster of trees each growing additional branches from its own trunk, will usually do much better than a company working on a number of unrelated new products which, if successful, will land it in sev...

AbbVie ( ABBV ) is in the process of acquiring Allergan ( AGN ) for a combination of $120.30 in cash and 0.866 shares of ABBV. To date, the deal has secured approvals from China, Brazil, Canada, Ukraine, and Allergan shareholders. The deal does not require a vote of the buyer’s sharehol...

Roche ( RHHBY ) has been quite busy in 2019 and it is apparent that it is making a hard push towards building a pipeline of gene therapies. This involves two major deals this year dealing specifically with gene therapy companies. Both of these were large ones, and it shows the commitment of Ro...

Merger activity increased, with nine new deals announced and six deals closing. Deal Statistics New Deals The acquisition of LogMeIn (LOGM) by Francisco Partners for $4.3 billion or $86.05 per share in cash. We added LOGM as a potential deal to the Deals in the Works section on Dece...

This article explains the reasons behind the movement in a selection of the largest U.S. cash merger arbitrage spreads from the past week as calculated by Merger Arbitrage Limited. We analyze the attractiveness and profitability of each spread going forward and indicate the trading position or...

As one of the largest pharma companies out there, I suppose it stands to reason that Roche ( OTCQX:RHHBY ) would have an above-average level of newsflow, but tracking the developments at Roche over the last couple of months has been like trying to sip from a firehose. It’s well worth ...